Max Jonson

Bure Equity AB Private Equity (BEPE) is the private equity investment division of the Swedish firm, Bure Equity AB (ST: BURE). In 1992, the firm was founded as Bure Förvaltnings AB. In 2000, the firm changed their name to Bure Equity AB and decided to focus entirely on private equity investments. BEPE specializes in long-term ownership of unlisted firms. They operate from offices in Stockholm, Sweden.

Bure Equity AB Private Equity (BEPE) is the private equity investment division of the Swedish firm, Bure Equity AB (ST: BURE). In 1992, the firm was founded as Bure Förvaltnings AB. In 2000, the firm changed their name to Bure Equity AB and decided to focus entirely on private equity investments. BEPE specializes in long-term ownership of unlisted firms. They operate from offices in Stockholm, Sweden.

Bure Growth AB invests in development companies. The firm was founded in 2014 and is headquartered in Stockholm, Sweden.

BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.

Bure Equity AB Private Equity (BEPE) is the private equity investment division of the Swedish firm, Bure Equity AB (ST: BURE). In 1992, the firm was founded as Bure Förvaltnings AB. In 2000, the firm changed their name to Bure Equity AB and decided to focus entirely on private equity investments. BEPE specializes in long-term ownership of unlisted firms. They operate from offices in Stockholm, Sweden.

BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.

BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.

Bure Equity AB Private Equity (BEPE) is the private equity investment division of the Swedish firm, Bure Equity AB (ST: BURE). In 1992, the firm was founded as Bure Förvaltnings AB. In 2000, the firm changed their name to Bure Equity AB and decided to focus entirely on private equity investments. BEPE specializes in long-term ownership of unlisted firms. They operate from offices in Stockholm, Sweden.

Bure Equity AB Private Equity (BEPE) is the private equity investment division of the Swedish firm, Bure Equity AB (ST: BURE). In 1992, the firm was founded as Bure Förvaltnings AB. In 2000, the firm changed their name to Bure Equity AB and decided to focus entirely on private equity investments. BEPE specializes in long-term ownership of unlisted firms. They operate from offices in Stockholm, Sweden.

Bure Equity AB Private Equity (BEPE) is the private equity investment division of the Swedish firm, Bure Equity AB (ST: BURE). In 1992, the firm was founded as Bure Förvaltnings AB. In 2000, the firm changed their name to Bure Equity AB and decided to focus entirely on private equity investments. BEPE specializes in long-term ownership of unlisted firms. They operate from offices in Stockholm, Sweden.

BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.

BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.

Bure Equity AB Private Equity (BEPE) is the private equity investment division of the Swedish firm, Bure Equity AB (ST: BURE). In 1992, the firm was founded as Bure Förvaltnings AB. In 2000, the firm changed their name to Bure Equity AB and decided to focus entirely on private equity investments. BEPE specializes in long-term ownership of unlisted firms. They operate from offices in Stockholm, Sweden.

BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.